Last updated on June 2018

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy

Brief description of study

This is a multi-site, placebo-controlled, double-blind, randomized-withdrawal study evaluating the durability of clinical benefit of a study drug for patients with symptomatic neurogenic orthostatic hypotension. This study has a duration of up to 36 weeks, consisting of 5 periods: 

  1. Screening Period: up to 4 weeks duration; 
  2. Open-Label Titration Period (Titration Period): up to 4 weeks duration; 
  3. Open-Label Treatment Period (Open-Label Period): 12 weeks duration; 
  4. Double-Blind Treatment Period (Double-Blind Period): 12 weeks duration; 
  5. Safety Follow-Up Period: 4 weeks duration.

Clinical Study Identifier: TX207239

Find a site near you

Start Over

EvergreenHealth Research Program

12039 NE 128th Street, Suite 300 Kirkland, WA USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.